Aquavit has submitted an investigational new drug (IND) application to the Food and Drug Administration (FDA) for the initiation of its Phase II/III study of Dermatox (aqubotulinumtoxinA), an intradermal injection of botulinum toxin.
NEW YORK, April 28, 2023 /PRNewswire/ -- Aquavit Holdings (Aquavit), a biotechnology company focused on the development of botulinum toxin applications, announced today that it has filed an Investigational New Drug Application with the FDA for its flagship intradermal injection of botulinum toxin, Dermatox™ (aqubotulinumtoxinA). AqubotulinumtoxinA has already received regulatory approvals in other countries in Asia, South America and the Middle East, and is currently under phase III clinical trials in many other territories.
NEW YORK, March 17, 2023 /PRNewswire/ -- Aquavit Holdings, the exclusive licensee of Huons Global's Botulinum Toxin in the USA and Canada, will officially unveil the Aquatox™ program at the Annual American Academy of Dermatology - 2023, the world's largest dermatology conference scheduled from March 17-21, 2023, in New Orleans, LA.
NEW YORK, March 24, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. announced today that it has submitted its IND package (Investigation of New Drug) for a new botulinum toxin (DTX-021) to the FDA for approval.
NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a first-of-its-kind microchannel drug delivery technology, recently announced that the company received a notice of allowance through the USPTO's Fast-Track Prioritized Examination Pilot Program (PEPP) for the application of the company's proprietary technology for self-injectable Covid 19 vaccination (AQV-1122.)